Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)

Antiviral Therapy

Volumn 11, Issue 5, 2006, Pages 619-623

  Gripshover, Barbara M ^a   Ribaudo, Heather ^b   Santana, Jorge ^c   Gerber, John G ^d   Campbell, Thomas B ^d   Hogg, Evelyn ^e   Jarocki, Bernadette ^f   Hammer, Scott M ^g   Kuritzkes, Daniel R ^h  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d UNIVERSITY OF COLORADO   (United States)

^e ACTG Operations Center   (United States)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMDOXOVIR; ENFUVIRTIDE; PLACEBO; RITONAVIR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DOUBLE BLIND PROCEDURE; ENCEPHALITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MALE; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TREATMENT FAILURE;

ADULT; CD4 LYMPHOCYTE COUNT; DIOXOLANES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PILOT PROJECTS; PURINE NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 33747785298     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Mewshew JP, Myrick FT, Wakefield DA, et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 from patients for whom nucleoside therapy fails. J Acquir Immune Defic Syndr 2002; 29:11-20.
2. Gu Z, Wainberg MA, Nguyen-Ba N, et al. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother 1999; 43:2376-2382.
3. Bazmi, HZ, Hammond JL, Cavalcanti SCH, Chu CK, Schinazi RF, Mellors JW. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane- guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 2000; 44:1783-1788.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
5. Division of AIDS table for grading severity of adult adverse experiences. August 1992. Rockville, MD: National Institute of Allergy and Infectious Diseases.
6. Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthal 1993; 111:831-836.
7. Lalezari JP, Henrt K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
8. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.